Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
|Effective start/end date||1/1/18 → 1/31/24|
- BIG TEN CANCER RESEARCH CONSORTIUM
- BRISTOL-MYERS SQUIBB PHARM RES
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.